Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07816367) titled 'A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine' on Sept. 7.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
Primary Sponsor: Kallyope Inc.
Condition:
Migraine
Intervention:
Drug: Elismetrep
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: September 2026
Target Sample Size: 1500
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT0781636...